Skip to main content
SpringerLink
Log in

Prevention of Type 2 Diabetes

  • Chapter
  • First Online:
Diabetes and Exercise

Part of the book series: Contemporary Diabetes ((CDI))

  • 2544 Accesses

Abstract

The numbers of people with type 2 diabetes are rising rapidly around the world, making it imperative to develop and introduce methods of preventing the condition. A series of clinical trials over the last decade has shown conclusively that lifestyle interventions focusing on physical activity, diet, and weight loss can reduce the risk of developing type 2 diabetes by approximately 60%. Trials examining pharmaceutical interventions have shown that metformin, acarbose, and glitazones also reduce the risk of developing diabetes, but have shown no benefit of ACE inhibitors. Although uncertainty remains about the widespread use of pharmaceutical agents for diabetes prevention, programmes to implement lifestyle changes in those at high risk of developing type 2 diabetes now need to be put in place.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sicree R, Shaw JE, Zimmet PZ: Diabetes and impaired glucose tolerance. In Diabetes Atlas, 3rd ed. Gan D, Ed. Brussels, International Diabetes Federation, 2006, 10–149.

    Google Scholar 

  2. Riste L, Khan F, Cruickshank K: High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 24:1377–1383, 2001.

    Article  PubMed  CAS  Google Scholar 

  3. Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Gareeboo H, Alberti KG, Shaw JE: Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabetes Med 22:61–68, 2005.

    Article  CAS  Google Scholar 

  4. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasannakumar KM, Nair JD: High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 44:1094–1101, 2001.

    Article  PubMed  CAS  Google Scholar 

  5. Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K: The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 66:301–307, 2004.

    Article  PubMed  CAS  Google Scholar 

  6. Salme ron J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB, Willett WC: Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73:1019–1026, 2001.

    CAS  Google Scholar 

  7. Salmerón J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willet WC: Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277:472–477, 1997.

    Article  PubMed  Google Scholar 

  8. Perry I, Wannamethee S, Walker M, Thomson AG, Whincup PH, Shaper AG: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. Br J Med 310:560–564, 1995.

    Article  CAS  Google Scholar 

  9. O'Dea K: Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes 33:596–603, 1984.

    Article  PubMed  Google Scholar 

  10. Sartor G, Scherstén B, Carlström S, Melander A, Nordén Å, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41–49, 1980.

    Article  PubMed  CAS  Google Scholar 

  11. Bourn D, Mann J, McSkimming B, Waldron M, Wishart J: Impaired glucose tolerance and NIDDM: does a lifestyle intervention have and effect? Diabetes Care 17:1311–1319, 1994.

    Article  PubMed  CAS  Google Scholar 

  12. Torjesen P, Birkeland K, Anderssen S, Hjermann I, Holme I, Urdal P: Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo diet and exercise study: a randomized trial. Diabetes Care 20:26–31, 1997.

    Article  PubMed  CAS  Google Scholar 

  13. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891–898, 1991.

    Article  PubMed  CAS  Google Scholar 

  14. Pan X, Li G, Hu Y, Wang J, Yang W, An Z, Hu Z, Lin J, Xiao J, Cao H, Liu P, Jiang X, Wang J, Zheng H, Zhang H, Bennett P, Howard B: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 20:537–544, 1997.

    Article  PubMed  CAS  Google Scholar 

  15. Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V: Finnish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350, 2001.

    Article  PubMed  CAS  Google Scholar 

  16. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679, 2006.

    Article  PubMed  Google Scholar 

  17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403, 2002.

    Article  PubMed  CAS  Google Scholar 

  18. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:2102–2107, 2006.

    Article  PubMed  Google Scholar 

  19. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297, 2006.

    Article  PubMed  CAS  Google Scholar 

  20. Kosaka K, Noda M, Kuzuya T: Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152–162, 2005.

    Article  PubMed  Google Scholar 

  21. Long S, O'Brien K, MacDonald K, Leggett-Frazier N, Swanson M, Pories W, Caro J: Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal intervention study. Diabetes Care 17:372–375, 1994.

    Article  PubMed  CAS  Google Scholar 

  22. Sjostrom CD, Lissner L, Wedel H, Sjostrom L: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 7:477–484, 1999.

    PubMed  CAS  Google Scholar 

  23. Dixon JB, O'Brien PE: Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 25:358–363, 2002.

    Article  PubMed  Google Scholar 

  24. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161, 2004.

    Article  PubMed  CAS  Google Scholar 

  25. Fajans SS, Conn JW: Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 9:83–88, 1960.

    PubMed  CAS  Google Scholar 

  26. Engelhardt HT, Vecchio TJ: The long-term effect of Tolbutamide on glucose tolerance in adult, asymptomatic, latent diabetics. Metabolism 14:885–890, 1965.

    Article  PubMed  CAS  Google Scholar 

  27. Belknap B, Bagdade J, Amaral J, Bierman E: Plasma lipids and mild glucose intolerance II: a double blind study of the effect of tolbutamide and placebo in mild adult diabetic outpatients. Excepta Med Int Congr Ser 149:171–176, 1967.

    Google Scholar 

  28. Paasikivi J, Wahlberg F: Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 7:323–327, 1971.

    Article  PubMed  CAS  Google Scholar 

  29. Keen H, Jarrett R, McCartney P: The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia 22:73–78, 1982.

    Article  PubMed  CAS  Google Scholar 

  30. Camerini-Davalosra R: Treatment of chemical diabetes. Exepta Med Int Congr Ser 149:228–242, 1967.

    Google Scholar 

  31. Jarrett RJ, Keen H, Fuller JH, McCartney M: Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin. Br Med J 2:861–865, 1977.

    Article  PubMed  CAS  Google Scholar 

  32. Papoz L, Job D, Eschwege E, Aboulker JP, Cubeau J, Pequignot G, Rathery M, Rosselin G: Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia 15:373–380, 1978.

    Article  PubMed  CAS  Google Scholar 

  33. Ratzmann KP, Witt S, Schulz B: The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabete Metab 9:87–93, 1983.

    PubMed  CAS  Google Scholar 

  34. Cederholm J: Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea. Ups J Med Sci 90:229–242, 1985.

    Google Scholar 

  35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077, 2002.

    Article  PubMed  CAS  Google Scholar 

  36. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977–980, 2003.

    Article  Google Scholar 

  37. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150–1156, 2005.

    Article  PubMed  Google Scholar 

  38. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796–2803, 2002.

    Article  PubMed  CAS  Google Scholar 

  39. Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H, Zaojun Y, Fan W, Guangwei L, Xiaoren P: The preventive effect of Acarbose and Metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17:131–136, 2001.

    Google Scholar 

  40. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882–1885, 2001.

    Article  PubMed  CAS  Google Scholar 

  41. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562, 2006.

    Article  PubMed  Google Scholar 

  42. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105, 2006.

    Article  PubMed  CAS  Google Scholar 

  43. Wylie-Rosett J, Herman WH, Goldberg RB: Lifestyle intervention to prevent diabetes: intensive and cost effective. Curr Opin Lipidol 17:37–44, 2006.

    Article  PubMed  CAS  Google Scholar 

  44. Shaw J, Zimmet P, de Courten M, Dowse G, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti K: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402, 1999.

    Article  PubMed  CAS  Google Scholar 

  45. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P: Cardiovascular risk factor changes in Finland, 1972–1997. Int J Epidemiol 29:49–56, 2000.

    Article  PubMed  CAS  Google Scholar 

  46. Uusitalo U, Feskens E, Tuomilehto J, Dowse G, Haw U, Fareed D, Hemraj F, Gareeboo H, Alberti K, Zimmet P: Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: cross sectional survey. BMJ 313:1044–1046, 1996.

    Article  PubMed  CAS  Google Scholar 

  47. Home PD , Pocock SJ , Beck-Nielsen H , et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) Study: interim findings on cardovascular hospitalizations and deaths. N Engl J Med 357 : 28–38 , 2007

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, International Diabetes Institute and Monash University, Melbourne, VIC, Australia

    Jonathan E. Shaw

  2. Department of Medicine, Monash University, Box Hill Hospital, Melbourne, VIC, Australia

    Richard W. Simpson

Authors
  1. Jonathan E. Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard W. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Divisions of General Internal Medicine and Cardiology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA

    Judith G. Regensteiner PhD

  2. Division of Endocrinology Metabolism and Diabetes, Department of Medicine, Aurora, CO, USA

    Jane E.B. Reusch MD

  3. Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Kerry J. Stewart EDD

  4. Joslin-Beth Israel Deaconess Foot Center, Microcirculation Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Aristidis Veves MD, DSc

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shaw, J.E., Simpson, R.W. (2009). Prevention of Type 2 Diabetes. In: Regensteiner, J.G., Reusch, J.E., Stewart, K.J., Veves, A. (eds) Diabetes and Exercise. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59745-260-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-260-1_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-926-0

  • Online ISBN: 978-1-59745-260-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation